Diagnostic solutions are at the forefront as Roche and Hitachi High-Tech have renewed their long-standing partnership with a new ten-year contract to jointly develop and manufacture advanced diagnostic solutions. This collaboration, which has been successful for 46 years, has produced several innovative analysers, including the widely used Cobas systems for in vitro diagnostic assays.
The companies plan to introduce new analytical units later this year, including the cobas c 703 and cobas ISE neo, along with a fully automated mass spectrometry integration, the cobas Mass Spec solution. These additions are expected to enhance diagnostic capabilities and streamline processes in medical laboratories.
Diagnostic Market Growth: Roche and Hitachi Collaboration to Capitalize on $49.6 Billion Industry
The in vitro diagnostics market was valued at approximately $49.6 billion in 2022, with the in vitro diagnostic analyser segment contributing around $4.8 billion. This segment is projected to grow significantly, reaching over $7.8 billion in sales by 2033, according to GlobalData analysis. The collaboration between Roche and Hitachi is poised to capitalize on this growth by providing cutting-edge diagnostic tools to healthcare providers worldwide.
Palani Kumaresan, head of Roche Diagnostic Solutions, expressed enthusiasm about the renewed agreement, stating, “I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care. Together, we have built an unrivalled installed base of more than 84,000 diagnostic platforms around the globe. This brings both speed and scale to testing for our customers, helping them to better serve patients’ needs.”
Roche has been expanding its portfolio of molecular assays, which are operated on cobas systems, receiving multiple approvals from the US Food and Drug Administration (FDA) in recent months. In March, Roche received US approval for the first-ever blood screening test for malaria, which is conducted on the PCR-based cobas 6800/8800 systems. This test allows healthcare professionals to screen for malaria in blood, organ, and tissue donors, enhancing the safety of these procedures.
Diagnostic Advancements: Roche’s Blood Test Portfolio Includes Advanced Immunoassays
Roche’s blood test portfolio also includes various immunoassays, such as:
- Elecsys HBeAg quant for diagnosing and monitoring hepatitis B.
- Anti-HEV IgM and Elecsys Anti-HEV IgG for detecting hepatitis E virus (HEV) infections.
- Neurofilament light chain (NfL) test for diagnosing multiple sclerosis.
- Interleukin 6 (IL-6) immunoassay for diagnosing neonatal sepsis.
These tests are run on different cobas e analysers, showcasing Roche’s commitment to expanding its diagnostic capabilities and improving patient care.
The renewed partnership with Hitachi High-Tech underscores Roche’s strategic approach to maintaining its leadership in the diagnostics market. By combining Roche’s expertise in diagnostic solutions with Hitachi’s technological innovations, the collaboration aims to develop more efficient and effective diagnostic tools.
Looking ahead, the partnership between Roche and Hitachi High-Tech is set to drive significant advancements in the field of diagnostics. With the launch of the new analytical units and the continued expansion of Roche’s diagnostic portfolio, healthcare providers will have access to more precise and reliable tools for disease detection and management.
The introduction of the cobas c 703, cobas ISE neo, and the cobas Mass Spec solution will likely streamline diagnostic processes, reduce turnaround times, and improve patient outcomes. As the demand for advanced diagnostic solutions continues to grow, the collaboration between Roche and Hitachi is well-positioned to meet the evolving needs of the healthcare industry.
Roche and Hitachi High-Tech’s renewed partnership and upcoming launches of new diagnostic analysers highlight their commitment to advancing medical technology and improving patient care. The strategic collaboration aims to provide innovative solutions that enhance diagnostic accuracy, efficiency, and accessibility, benefiting healthcare providers and patients worldwide. With a strong foundation of 46 years of successful collaboration, the future looks promising for this dynamic partnership in the rapidly evolving field of diagnostics.
Resource: Prnewswire, May 27, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
